Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
MRK Merck & Co., Inc. weekly Stock Chart
MRK [NYSE]
Merck & Co., Inc.
Healthcare | Drug Manufacturers - General | USA
statements
IndexDJIA S&P500 P/E19.21 EPS (ttm)3.98 Insider Own0.10% Shs Outstand2.53B Perf Week-4.27%
Market Cap193.22B Forward P/E12.67 EPS next Y6.03 Insider Trans-4.24% Shs Float2.52B Perf Month-5.58%
Income10.20B PEG3.20 EPS next Q1.08 Inst Own77.40% Short Float0.75% Perf Quarter-6.10%
Sales48.08B P/S4.02 EPS this Y58.90% Inst Trans-1.17% Short Ratio1.38 Perf Half Y-10.44%
Book/sh10.35 P/B7.38 EPS next Y13.28% ROA12.10% Target Price93.94 Perf Year-5.74%
Cash/sh2.94 P/C26.00 EPS next 5Y6.00% ROE38.10% 52W Range65.25 - 92.64 Perf YTD-16.03%
Dividend2.44 P/FCF61.75 EPS past 5Y-1.10% ROI19.20% 52W High-17.56% Beta0.51
Dividend %3.19% Quick Ratio0.90 Sales past 5Y2.10% Gross Margin72.20% 52W Low17.04% ATR1.97
Employees71000 Current Ratio1.10 Sales Q/Q11.50% Oper. Margin25.50% RSI (14)47.66 Volatility1.82% 2.39%
OptionableYes Debt/Eq1.07 EPS Q/Q10.30% Profit Margin21.10% Rel Volume0.44 Prev Close76.55
ShortableYes LT Debt/Eq0.83 EarningsApr 28 BMO Payout58.30% Avg Volume13.69M Price76.37
Recom1.90 SMA20-2.83% SMA50-1.29% SMA200-8.48% Volume6,054,306 Change-0.24%
Feb-27-20Initiated Barclays Overweight $93
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
May-24-20 02:40PM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-22-20 07:46AM  Telehealth is going to 'become the default' for patients: Ro CEO Yahoo Finance
May-21-20 03:48PM  Fmr. CDC Official: 'were not cutting any corners' on COVID-19 vaccine development Yahoo Finance Video
02:24PM  Clovis Oncology Needs a Savior GuruFocus.com
May-20-20 09:23AM  Here are the hot dogs that hedge funds have used to outperform this year MarketWatch
09:02AM  AstraZeneca, Merck Announce FDA Approval of Prostate Cancer Drug TheStreet.com
07:58AM  AstraZeneca and Merck's Lynparza gets FDA approval for prostate cancer MarketWatch
07:05AM  Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients GlobeNewswire
06:55AM  LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone Business Wire
06:26AM  AstraZeneca-Merck Lynparza Prostate Cancer Treatment Gets FDA Approval SmarterAnalyst
May-19-20 03:18PM  Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example' Yahoo Finance Video
03:15PM  Dow's 100-point drop led by losses for Merck, Procter & Gamble shares MarketWatch
02:14PM  Dow down 36 points on losses for shares of Merck, Procter & Gamble MarketWatch
01:16PM  7 Stocks Elfun Trusts Continues to Buy GuruFocus.com
01:04PM  Dow falls nearly 100 points on losses for shares of Merck, Home Depot MarketWatch
11:53AM  Dow falls 25 points on losses in Exxon Mobil, Chevron stocks MarketWatch
10:33AM  CORRECTING and REPLACING Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer Business Wire
07:00AM  Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship Business Wire
May-18-20 02:54PM  We anticipate a U-Shaped to Swoosh-Shaped recovery: Strategist Yahoo Finance Video
02:47PM  Moderna COVID-19 vaccine data is baby-step in right direction: Expert Yahoo Finance Video
May-15-20 03:13PM  U.S. FDA approves Bristol Myers' combo therapy for lung cancer Reuters
03:09PM  Trump unveils vaccine effort, says country will be back on its feet with or without one Yahoo Finance Video
02:54PM  Merck's (MRK) Keytruda Successful in Several Cancer Studies Zacks
May-14-20 02:47PM  American Express, UnitedHealth share gains contribute to Dow's 65-point climb MarketWatch
02:15PM  8 Dividend Stocks That Split the Difference Between Yield and Safety Barrons.com
01:46PM  Merck's Top Cancer Therapy Takes Another Big Leap Forward Motley Fool
10:46AM  Merck, Roche, Amgen Stocks React to Release of Cancer-Drug Data Barrons.com
08:44AM  Merck KGaA says profit could slip as fertility treatments shunned Reuters
06:55AM  Merck Just Made a Gamble That Smart Investors Should Bet on Too Motley Fool
06:45AM  Merck to Present at the UBS Virtual Global Healthcare Conference Business Wire
May-13-20 05:03PM  Dow Jones Falls Over 500 Points on Wednesday GuruFocus.com
05:00PM  New Combination Data for Mercks KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC Business Wire
05:00PM  Mercks Novel HIF-2 Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma Business Wire
05:00PM  Mercks KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial Business Wire
05:00PM  Mercks KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negative Breast Cancer Business Wire
02:00AM  Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals Business Wire
May-11-20 05:40PM  US Indexes Post Some Gains Monday GuruFocus.com
May-10-20 08:51AM  AstraZeneca-Merck Ovarian Cancer Treatment Gets FDA Approval SmarterAnalyst
May-08-20 05:25PM  LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer Business Wire
04:59PM  Stocks jump despite a record 20.5M jobs lost in April Yahoo Finance Video
06:45AM  Merck Announces Virtual 2020 Annual Shareholders Meeting Business Wire
May-07-20 05:42PM  Analysts See Seattle Genetics Profitable in 2022 GuruFocus.com
02:45PM  Stocks surge despite another grim jobless claims report Yahoo Finance Video
09:55AM  Is Merck & Co., Inc.'s (NYSE:MRK) CEO Paid At A Competitive Rate? Simply Wall St.
06:59AM  Bristol Myers sees 2020 earnings holding despite coronavirus pandemic Reuters
06:55AM  Merck to Present at the BofA Securities 2020 Health Care Conference Business Wire
06:45AM  Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program Business Wire
06:41AM  2 Beaten-Down Stocks to Buy Right Now Motley Fool
06:00AM  Express Scripts' 'Parachute' to cap prescription costs for those hit by coronavirus turmoil Yahoo Finance
05:00AM  Cigna's Express Scripts offers discounted drugs for U.S. newly unemployed Reuters
May-06-20 07:00AM  Ferring's therapy curbs recurrent superbug infection - study Reuters
06:45AM  Results of Phase 3 Trial Evaluating the Efficacy and Safety of Mercks RECARBRIO (Imipenem, Cilastatin, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Available Business Wire
May-05-20 06:45AM  Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities Business Wire
May-04-20 03:12PM  Trump expresses confidence for coronavirus vaccine by the end of the year Yahoo Finance Video
11:33AM  Thoughts on Merck's Strong First Quarter GuruFocus.com
11:09AM  Merck Beats on Earnings, Stock Stays Below 200-Day SMA Investopedia
May-01-20 08:39AM  Did Merck Just Receive a Gift From the FDA? Motley Fool
Apr-30-20 03:40PM  Los Angeles makes coronavirus testing available Yahoo Finance Video
12:49PM  NJ's Murphy sees coronavirus persisting, says 'deep relationship' with feds needed Yahoo Finance
10:03AM  Pfizer aims for 10-20 mln doses of coronavirus vaccine by end-2020 depending on trials Reuters
09:57AM  Hedge Fund Manager: Merck Is Slightly Attractive But Close To Fair Value Insider Monkey
Apr-29-20 04:05PM  U.S. FDA gives broader approval to GSK's Zejula for ovarian cancer Reuters
11:04AM  Merck Analysts Focus On Fundamentals, Keytruda Strength Following Guidance Cut Benzinga
08:57AM  Edited Transcript of MRK earnings conference call or presentation 28-Apr-20 12:00pm GMT Thomson Reuters StreetEvents
Apr-28-20 05:24PM  Wall Street Turns Red on Tuesday GuruFocus.com
04:46PM  US STOCKS-Wall Street down on flight from techs; move to value limits loss on Dow, S&P 500 Reuters
04:41PM  Merck Reports First-Quarter Results, Lowers Guidance Motley Fool
04:35PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications Business Wire
03:04PM  Coronavirus update: German infection rate ticks higher after reopening moves, offers lesson to U.S. governors MarketWatch
03:00PM  Merck & Co Inc (MRK) Q1 2020 Earnings Call Transcript Motley Fool
02:30PM  US STOCKS-S&P 500 gains modestly, warning of higher COVID-19 deaths curb recovery hopes Reuters
01:36PM  US STOCKS-Fears of surge in coronavirus death toll weigh on S&P, Nasdaq Reuters
12:57PM  One Biotech Stock Is Up 57% After Presenting at a Big Cancer Conference. Heres Why. Barrons.com
12:39PM  Merck Warns That Slowdown in Medical Care Will Hurt Its Sales Bloomberg
12:04PM  US STOCKS-S&P 500, Nasdaq retreat as pandemic damage mounts Reuters
12:00PM  How to Trade Merck Shares After Sales Warning TheStreet.com
11:51AM  Dow flat despite losses for shares of Merck, Intel MarketWatch
11:05AM  Dow erases 380-point gain Tuesday morning as tech-related and health-care shares drag stock market lower MarketWatch
10:46AM  US STOCKS-S&P 500, Dow gain on upbeat corporate earnings, reopening hopes Reuters
10:43AM  Earnings Data Deluge Zacks
10:24AM  A Plethora of Q1 Earnings Results: MMM, CAT, PEP & More Zacks
09:36AM  Dow jumps more than 300 points at Tuesday's open, nears best level since early March as lockdown easing fuels bulls MarketWatch
09:25AM  Dow's earnings reporters add nearly a net 50 points to the Dow's price, led by 3M's stock rally MarketWatch
07:18AM  Merck sees $2.1 billion coronavirus hit to 2020 sales Reuters
07:08AM  Merck sees $2.1 billion hit to full-year sales from coronavirus pandemic Reuters
07:08AM  Merck profit rises, cuts 2020 forecast over COVID-19 uncertainty Reuters
07:01AM  Merck's stock gains after profit and sales beat, but outlook is downbeat MarketWatch
06:59AM  Merck profit rises, cuts 2020 forecast over COVID-19 uncertainty Reuters
06:45AM  Merck Announces First-Quarter 2020 Financial Results Business Wire
06:34AM  US STOCKS-Futures jump with focus on earnings, easing lockdowns Reuters
Apr-27-20 04:08PM  Coronavirus update: Optimism over phased reopenings only slightly tempered by continued concerns over inadequate testing for COVID-19 virus MarketWatch
10:43AM  Big Drug Stock Q1 Earnings Due on Apr 28: MRK, PFE and NVS Zacks
10:15AM  Merck and Pfizer Stocks Head Up a Busy Earnings Week Investopedia
09:44AM  Apple And Amazon Earnings, Fed Meeting Among Highlights In Busy Week Ahead Benzinga
07:27AM  Shares of Merck gain on COVID-19 research collaboration MarketWatch
06:55AM  First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Mercks KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I Business Wire
06:45AM  Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers Business Wire
02:35AM  New York trial tests heartburn medication against COVID-19 MarketWatch
Apr-24-20 10:49AM  Dow flat despite gains in Home Depot, Apple Inc. stocks MarketWatch
06:55AM  LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer Business Wire
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through Pharmaceutical and Animal Health segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products for swine; and dog, cat, and horse vaccines. Additionally, the company offers services and solutions that focus on engagement, clinical, and health analytics. Merck & Co., Inc. has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; and Skyhawk Therapeutics, Inc. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers; and physicians and physician distributors, veterinarians, and animal producers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRUN LESLIE ADirectorMay 07Option Exercise0.005,00006,948May 07 04:48 PM
WEEKS WENDELL PDirectorMay 07Option Exercise0.005,00005,100May 07 04:50 PM
BRUN LESLIE ADirectorMay 07Sale75.465,000377,3001,948May 07 04:48 PM
WEEKS WENDELL PDirectorMay 07Sale76.025,000380,104100May 07 04:50 PM
Nally MichaelEVP, Chief Marketing OfficerMay 05Option Exercise76.862,345180,23712,054May 06 05:14 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 05Option Exercise76.863,283252,33129,401May 06 05:15 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 05Option Exercise76.861,29099,1497,304May 06 05:16 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 05Option Exercise76.863,752288,37982,611May 06 05:17 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise77.671,904147,88479,797May 06 05:17 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise77.6769253,7486,252May 06 05:16 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise77.671,21294,13626,715May 06 05:15 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise77.675,772448,3119,489May 06 05:13 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise77.671,298100,81610,274May 06 05:14 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 03Option Exercise77.6787567,96125,934May 05 04:48 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 03Option Exercise77.671,541119,6896,089May 05 04:42 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJan 13Option Exercise0.0082,5480139,111Jan 15 05:15 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJan 13Sale89.34102,0739,118,86537,038Jan 15 05:15 PM
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise0.002,28706,196Nov 01 05:07 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise0.004,57404,574Nov 01 05:07 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise0.002,287073,032Nov 01 05:06 PM
Scholefield James HEVP,Chief Info&Digital OfficerOct 30Option Exercise0.0011,436011,436Nov 01 05:04 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Option Exercise0.006,427077,951Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Sale85.096,427546,85071,524Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Option Exercise0.0031,6990103,223Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Sale85.0131,6992,694,78971,524Aug 12 05:13 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Option Exercise0.00216,7180354,378Jun 27 05:05 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Sale85.43216,71818,514,032137,660Jun 27 05:05 PM
open in yahoo | open in reuters | open in google